{"id":30289,"date":"2026-03-23T12:50:08","date_gmt":"2026-03-23T16:50:08","guid":{"rendered":"https:\/\/aafa.org\/?post_type=asthma_medicine&p=30289"},"modified":"2026-03-23T17:27:30","modified_gmt":"2026-03-23T21:27:30","slug":"depemokimab-ulaa-exdensur","status":"publish","type":"asthma_medicine","link":"https:\/\/aafa.org\/asthma-medicine\/depemokimab-ulaa-exdensur\/","title":{"rendered":"Depemokimab-Ulaa \u2013 EXDENSUR"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Main Content” _builder_version=”4.17.4″ _module_preset=”default” custom_padding=”2%||2%||true|false” global_colors_info=”{}”][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” admin_label=”Page Title” module_class=”tert-content q” _builder_version=”4.27.4″ _module_preset=”default” title_font=”|600|||||||” title_text_align=”left” title_text_color=”#008c99″ title_font_size=”39px” background_enable_image=”off” background_size=”contain” background_position=”center_left” module_alignment=”left” custom_margin=”||0px||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_post_title][et_pb_code admin_label=”Breadcrumbs” module_class=”bcrumb2″ _builder_version=”4.18.0″ _module_preset=”default” text_orientation=”left” custom_margin=”||||false|false” custom_padding=”||||false|false” custom_css_main_element=”font-size:16px;||color: #008c99;” global_module=”1658″ global_colors_info=”{}”][\/et_pb_code][et_pb_text admin_label=”Regular Content” _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#505050″ global_colors_info=”{}”]<\/p>\n

Drug Name<\/strong>: Depemokimab-ulaa<\/p>\n

Brand Name:<\/strong> EXDENSUR\u00ae<\/a><\/p>\n

Medicine Use:<\/strong> Add-on therapy\/long-term control<\/p>\n

Type of Medicine<\/strong>: Biologic<\/p>\n

Form<\/strong>: Injection<\/p>\n

Prescribing Info<\/strong>: EXDENSUR (depemokimab-ulaa) injection prescribing information insert<\/a>\"Download<\/p>\n

Note:<\/strong>\u00a0EXDENSUR is the first ultra-long-acting biologic approved for asthma. While most biologics are given every 2 to 4 weeks, EXDENSUR is given only twice a year (once every 6 months).<\/p>\n

Possible Side Effects:<\/strong>
Allergic reaction
Upper respiratory tract infection (common cold, sinus infection)
Sneezing, nasal congestion, runny nose, and nasal itching (allergic rhinitis)
Flu or flu-like symptoms
Joint pain
Sore throat<\/p>\n

[\/et_pb_text][et_pb_text admin_label=”Tan Callout Box” _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#505050″ link_font=”||||on|||#008c99|” link_text_color=”#008c99″ link_line_height=”1.7em” ul_line_height=”1.7em” header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” header_3_font=”|600|||||||” header_3_text_align=”left” header_3_text_color=”#008c99″ header_3_font_size=”28px” background_color=”#dbdbdb” custom_padding=”4%|4%|4%|4%|true|true” hover_enabled=”0″ box_shadow_style=”preset2″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

Copay Assistance Programs for EXDENSUR<\/h3>\n

If you have commercial insurance:<\/strong>\u00a0If you have a commercial medical or prescription insurance plan, you may be able to take part on the\u00a0EXDENSUR Copay Program<\/strong><\/a>.\u00a0If you are approved, the GSK Copay Program may help with your cost share for EXDENSUR, as well as provide access to ongoing patient support from a Patient Navigator.<\/p>\n

If you have government insurance or no insurance:\u00a0<\/strong>You are not eligible for this program if you are covered by any federal or state prescription insurance program.<\/p>\n

For more information, visit the EXDENSUR Copay Program<\/strong><\/a>\u00a0website or call\u00a0888-216-3003<\/strong>.<\/p>\n

Coverage Support<\/strong><\/p>\n

GSK can help check your insurance coverage and help you understand your benefits. You can reach out to a Patient Navigator at 844-225-5894<\/a>\u00a0<\/strong>(844-Call-TwGSK)<\/strong>.<\/a><\/p>\n

[\/et_pb_text][et_pb_code admin_label=”Print” module_id=”print” module_class=”clearfix” _builder_version=”4.17.6″ _module_preset=”default” global_module=”5156″ saved_tabs=”all” global_colors_info=”{}”]<\/svg> Print post<\/a> [\/et_pb_code][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.17.4″ _module_preset=”default” custom_padding=”6%||||false|false” global_colors_info=”{}”][et_pb_image src=”https:\/\/aafa.org\/wp-content\/uploads\/2026\/03\/exdensur-syringe.avif” alt=”Depemokimab-Ulaa \u2013 EXDENSUR ” title_text=”exdensur-syringe” show_in_lightbox=”on” admin_label=”Picture” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_links_to":"","_links_to_target":""},"medicine_use":[20],"type_of_medicine":[23],"class_list":["post-30289","asthma_medicine","type-asthma_medicine","status-publish","hentry","medicine_use-long-term-control","type_of_medicine-biologics"],"acf":[],"yoast_head":"\nDepemokimab-Ulaa \u2013 EXDENSUR - Asthma and Allergy Foundation of America<\/title>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\t\n